Results 71 to 80 of about 82,032 (316)

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X. [PDF]

open access: yes, 2008
BackgroundActivated factor X (FXa) is a vitamin K-dependent serine protease that plays a pivotal role in blood coagulation by converting prothrombin to thrombin. There are no reports of humans with complete deficiency of FX, and knockout of murine F10 is
Arruda, VR   +7 more
core   +2 more sources

Gene Therapy and Gene Editing in Type 1 Diabetes: CRISPR‐Based β‐Cell Replacement and Treg Immune Modulation Approaches

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease marked by the destruction of pancreatic β‐cells, resulting in lifelong dependence on exogenous insulin. Despite advances in insulin delivery and glucose monitoring technologies, patients remain at risk for acute and long‐term complications, underscoring the need for ...
Tzu‐Min Lin   +5 more
wiley   +1 more source

Clinical perspectives of emerging pathogens in bleeding disorders. [PDF]

open access: yes, 2006
As a result of immunological and nucleic-acid screening of plasma donations for transfusion-transmissible viruses, and the incorporation of viral reduction processes during plasma fractionation, coagulation-factor concentrates (CFC) are now judged safe ...
Bozzette, Samuel   +11 more
core   +1 more source

Von Willebrand Disease [PDF]

open access: yes, 2017
Von Willebrand Disease (VWD) is a blood clotting disorder characterized by low levels of the Von Willebrand Factor (VWF) in the blood. VWF is functions to bind platelets and promote clotting of the blood when vascular injury occurs.
Misla David, Ramon
core   +2 more sources

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF‐McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the diagnosis and management of VWD all utilised GRADE methodology.
Mark W. Skinner   +59 more
wiley   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients With Severe Haemophilia A: Results of an Interventional, Post‐Marketing Study

open access: yesHaemophilia, EarlyView.
ABSTRACT This is a plain language summary of the results of a trial of damoctocog alfa pegol (BAY 94–9027, Jivi).
Pål André Holme   +5 more
wiley   +1 more source

Factor 8 Gene Mutation Spectrum of 270 Patients with Hemophilia A: Identification of 36 Novel Mutations

open access: yesTurkish Journal of Hematology, 2020
Objective: Hemophilia A (HA) is the most severe X-linked inherited bleeding disorder caused by hemizygous mutations in the factor 8 (F8) gene. The aim of this study is to determine the mutation spectrum of the F8 gene in a large HA cohort from Turkey ...
Tahir Atik   +22 more
doaj   +1 more source

Heavy hematuria requiring cystectomy in a patient with hemophilia A: a case report and literature review [PDF]

open access: yes, 2015
BACKGROUND: Hemophilia A is an X-linked recessive disorder caused by a deficiency in factor VIII. Hemophilia A affects 1 in 5,000–10,000 males. Hematuria is frequent in hemophilia.
Kimitoshi Saito   +4 more
core   +1 more source

Central Nervous System Bleeding in Children With Haemophilia in Limited Resource

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Central nervous system (CNS) bleeding in children with haemophilia is a life‐threatening complication that may cause severe neurological sequelae or death. In resource‐limited settings, where prophylaxis is not universally accessible, its patterns and outcomes may differ from those in high‐income countries.
Patcharee Komvilaisak   +5 more
wiley   +1 more source

Enhancing the Evidence for Care in Underserved Bleeding Disorders Communities

open access: yesHaemophilia, EarlyView.
ABSTRACT Background Major advances in haemophilia care have not translated equitably across all populations. Individuals with rare bleeding disorders (RBDs), people living in low‐ and lower‐middle‐income countries (LMICs) and women and girls with inherited bleeding disorders (WGWBD) continue to face significant diagnostic, therapeutic and research ...
Johnny Mahlangu
wiley   +1 more source

Home - About - Disclaimer - Privacy